Atara Biotherapeutics
ATRA
151 hedge funds and large institutions have $1.24B invested in Atara Biotherapeutics in 2021 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 62 increasing their positions, 42 reducing their positions, and 19 closing their positions.
193% more call options, than puts
Call options by funds: $1.06M | Put options by funds: $363K
48% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 42
21% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 19
2% more funds holding
Funds holding: 148 → 151 (+3)
0.04% less ownership
Funds ownership: 4.18% → 4.15% (-0.04%)
27% less capital invested
Capital invested by funds: $1.7B → $1.24B (-$457M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$25.3M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$20.8M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$17.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.6M |
| 5 |
Renaissance Technologies
New York
|
+$8.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$32.9M |
| 2 |
Citigroup
New York
|
-$14.8M |
| 3 |
AG
Artal Group
Luxembourg
|
-$14.1M |
| 4 |
BG
Baupost Group
Boston,
Massachusetts
|
-$11.2M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.4M |
ATRA Hedge Fund Activity: Q1 2021 in Review
151 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q1 2021, worth a combined $1.24B — down 27% from $1.7B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ATRA positions and 19 closed out — a net gain of 4 holders — while 62 added to existing stakes and 42 trimmed.
The largest buyer was State Street, adding an estimated $25.3M. The largest seller was Consonance Capital Management, cutting an estimated $32.9M.
- 151 institutional investors held Atara Biotherapeutics (ATRA) as of Q1 2021, up from 148 in Q4 2020.
- Funds reported $1.24B of Atara Biotherapeutics stock for Q1 2021, down 27% quarter-over-quarter.
- 23 funds opened new Atara Biotherapeutics positions in Q1 2021 and 19 closed out, a net change of +4 holders.
- The largest Atara Biotherapeutics buyer in Q1 2021 was State Street, an estimated $25.3M added.
- The largest Atara Biotherapeutics seller in Q1 2021 was Consonance Capital Management, an estimated $32.9M sold.
Based on aggregated 13F filings for Q1 2021.